Revolution Medicines (RVMD) COO reports 4,847-share sale under Rule 10b5-1 plan

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Operating Officer Margaret Horn reported a sale of company stock in an insider filing. On 12/16/2025, she disposed of 4,847 shares of common stock at a price of $76.8173 per share. The filing states this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to cover tax withholding obligations triggered by the vesting of restricted stock units.

After this transaction, Horn beneficially owned 141,053 shares of Revolution Medicines common stock, which includes 61,226 restricted stock units. The form indicates the holdings are directly owned.

Insights

Equity Compensation & Insider Transactions Analyst

COO reports small 10b5-1 sale tied to RSU tax withholding.

The filing shows Margaret Horn, Chief Operating Officer of Revolution Medicines, Inc., sold 4,847 shares of common stock at $76.8173 per share on 12/16/2025. The transaction code is "S", indicating a sale in the insider reporting framework.

The explanation states the sale was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy tax withholding obligations arising from RSU vesting after July 15, 2023. This frames the sale as a pre-planned, tax-related transaction rather than a discretionary open-market decision.

Following the sale, Horn beneficially owns 141,053 shares, including 61,226 restricted stock units, held directly. This indicates a continuing, sizable equity stake by the executive, while documenting the mechanical share sale related to equity compensation and taxes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Margaret A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		S(1)		4,847	D	$76.8173	141,053(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 61,226 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Margaret Horn	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider reporting this transaction for Revolution Medicines (RVMD)?

The insider is Margaret Horn, who serves as Chief Operating Officer of Revolution Medicines, Inc., as indicated in the relationship section of the filing.

What type of transaction did RVMD COO Margaret Horn report?

Margaret Horn reported a sale of common stock (transaction code "S") involving 4,847 shares of Revolution Medicines common stock on 12/16/2025.

At what price were the RVMD shares sold in this insider transaction?

The filing reports that the 4,847 shares of Revolution Medicines common stock were sold at a price of $76.8173 per share.

Was the RVMD insider sale made under a Rule 10b5-1 trading plan?

Yes. The explanation notes the transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, intended to satisfy tax withholding obligations from RSU vesting.

How many RVMD shares does Margaret Horn own after the reported transaction?

After the sale, Margaret Horn beneficially owns 141,053 shares of Revolution Medicines common stock, which the filing states includes 61,226 restricted stock units.

Does the filing specify whether Margaret Horn’s RVMD holdings are direct or indirect?

Yes. The amount of 141,053 shares beneficially owned following the transaction is reported with an ownership form of Direct (D).